CO2023007838A2 - Compuestos farmacéuticos - Google Patents

Compuestos farmacéuticos

Info

Publication number
CO2023007838A2
CO2023007838A2 CONC2023/0007838A CO2023007838A CO2023007838A2 CO 2023007838 A2 CO2023007838 A2 CO 2023007838A2 CO 2023007838 A CO2023007838 A CO 2023007838A CO 2023007838 A2 CO2023007838 A2 CO 2023007838A2
Authority
CO
Colombia
Prior art keywords
compounds
pharmaceutical compounds
agonists
muscarinic
salts
Prior art date
Application number
CONC2023/0007838A
Other languages
English (en)
Inventor
Charlotte Fieldhouse
Miles Stuart Congreve
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of CO2023007838A2 publication Critical patent/CO2023007838A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a compuestos que son agonistas del receptor muscarínico M1 y M4 y que son útiles en el tratamiento de enfermedades mediadas por los receptores muscarínicos M1 y/o M4. También se proporcionan composiciones farmacéuticas que contienen los compuestos y los usos terapéuticos de los compuestos. Los compuestos proporcionados son de fórmula (1): y sus sales.
CONC2023/0007838A 2020-12-18 2023-06-15 Compuestos farmacéuticos CO2023007838A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2020191.9A GB202020191D0 (en) 2020-12-18 2020-12-18 Pharmaceutical compounds
PCT/GB2021/053372 WO2022129951A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
CO2023007838A2 true CO2023007838A2 (es) 2023-10-30

Family

ID=74221349

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0007838A CO2023007838A2 (es) 2020-12-18 2023-06-15 Compuestos farmacéuticos

Country Status (16)

Country Link
EP (1) EP4263536A1 (es)
JP (1) JP2024504252A (es)
KR (1) KR20230121830A (es)
CN (1) CN116848109A (es)
AU (1) AU2021404194A1 (es)
CA (1) CA3202054A1 (es)
CL (1) CL2023001755A1 (es)
CO (1) CO2023007838A2 (es)
CR (1) CR20230256A (es)
DO (1) DOP2023000125A (es)
EC (1) ECSP23044370A (es)
GB (1) GB202020191D0 (es)
IL (1) IL303484A (es)
MX (1) MX2023007140A (es)
PE (1) PE20240646A1 (es)
WO (1) WO2022129951A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187451B2 (en) 2011-11-18 2015-11-17 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
JP2024504252A (ja) 2024-01-31
AU2021404194A1 (en) 2023-08-03
WO2022129951A1 (en) 2022-06-23
IL303484A (en) 2023-08-01
CN116848109A (zh) 2023-10-03
GB202020191D0 (en) 2021-02-03
CL2023001755A1 (es) 2024-01-05
PE20240646A1 (es) 2024-04-04
CR20230256A (es) 2023-09-29
US20220380379A1 (en) 2022-12-01
CA3202054A1 (en) 2022-06-23
KR20230121830A (ko) 2023-08-21
ECSP23044370A (es) 2023-08-31
EP4263536A1 (en) 2023-10-25
MX2023007140A (es) 2023-08-25
DOP2023000125A (es) 2023-08-31

Similar Documents

Publication Publication Date Title
DOP2023000125A (es) Compuestos farmacéuticos
CO2018002060A2 (es) Compuestos farmacéuticos
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
ECSP21004787A (es) Inhibidores de inflamasoma nlrp3
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
CR9098A (es) 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
CO2024001922A2 (es) Inhibidores de nlrp3
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
ECSP23030959A (es) Compuestos y su uso en el tratamiento del cáncer
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2022003041A1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
CL2022001307A1 (es) Compuestos antagonistas de receptores de adenosina.
UY30880A1 (es) 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones
CO2021001925A2 (es) Piridopirimidinas como inhibidores del receptor de histamina h4
UY39681A (es) Derivados de ciclobutilo 1,3–sustituidos y sus usos
AR123685A1 (es) Antagonistas del mrgx2
AR072535A1 (es) Compuestos de fenantrenona y composiciones farmaceuticas que los contienen
CL2021000282A1 (es) Inhibidores de ckd8/19